Related Experiment Video
Updated: Feb 11, 2026

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients
Published on: March 1, 2024
Successful Use of Adalimumab for Dissecting Cellulitis in a Pediatric Patient With Keratitis-Ichthyosis-Deafness
Sarah Lee1, Sarah Servattalab1,2, Yasin Damji1,2
1Harvard Medical School, Boston, Massachusetts, USA.
Abstract:
Dissecting cellulitis of the scalp (DCS) is a chronic inflammatory condition characterized by painful, draining nodules and progressive, scarring alopecia. It is often refractory to treatment, and there are currently no FDA-approved therapies. We present a case of a 15-year-old boy with keratitis-ichthyosis-deafness (KID) syndrome and DCS who experienced significant clinical response to treatment with adalimumab after failing multiple courses of oral antimicrobials, surgical interventions, intralesional corticosteroids, and topical therapies. Treatment with adalimumab led to reduction in drainage and pain and visible hair regrowth, highlighting its therapeutic potential in refractory, pediatric DCS including in the setting of syndromic skin disease.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Ecological Succession
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Nephrotic Syndrome I : Introduction

